share_log

Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short Interest

Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short Interest

Genmab A/S(OTCMKTS：GNMSF)湖上空頭股數大跌
kopsource ·  2022/09/28 21:43

Genmab A/S (OTCMKTS:GNMSF – Get Rating) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 10,900 shares, a decline of 71.7% from the August 31st total of 38,500 shares. Based on an average daily volume of 1,400 shares, the short-interest ratio is currently 7.8 days.

Genmab A/S(場外交易平臺：GNMSF-GET評級)是空頭股數9月份大幅下跌的目標。截至9月15日，空頭股數共有10,900股，比8月31日的38,500股下降了71.7%。以日均成交量1,400股計算，目前短息比率為7.8天。

Genmab A/S Price Performance

Genmab A/S性價比

Shares of Genmab A/S stock traded up $10.50 during trading on Wednesday, hitting $324.00. 822 shares of the stock were exchanged, compared to its average volume of 1,136. The stock has a market cap of $21.18 billion, a price-to-earnings ratio of 34.99 and a beta of 0.77. The firm's 50-day moving average price is $352.46 and its 200 day moving average price is $336.97. Genmab A/S has a 12-month low of $260.25 and a 12-month high of $479.99.

在週三的交易中，Genmab A/S的股價上漲了10.5美元，達到324.00美元。該股共成交822股，而其平均成交量為1,136股。該股市值為21.8億美元，市盈率為34.99倍，貝塔係數為0.77。該公司的50日移動均線價格為352.46美元，200日移動均線價格為336.97美元。Genmab A/S的12個月低點為260.25美元，12個月高位為479.99美元。

Get
到達
Genmab A/S
Genmab A/S
alerts:
警報：

Genmab A/S (OTCMKTS:GNMSF – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $452.87 million during the quarter. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%.

Genmab A/S(OTCMKTS：GNMSF-GET Rating)最近一次發佈季度收益數據是在8月10日星期三。該公司公佈該季度每股收益(EPS)為4.10美元。該業務本季度的收入為4.5287億美元。Genmab A/S的淨利潤率為38.42%，股本回報率為17.12%。

About Genmab A/S

關於Genmab A/S

(Get Rating)
(獲取評級)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Genmab A/S主要在丹麥開發用於治療癌症和其他疾病的抗體療法。該公司銷售用於治療多發性骨髓瘤(MM)患者的人類單抗DARZALEX；用於治療甲狀腺眼病的teprotomumab；用於治療慢性淋巴細胞白血病(CLL)和多發性硬化症的人類單抗Ofatumurnab；以及用於晚期或轉移性胃癌、食道癌和非小細胞肺癌的Amivantamab。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Genmab A/S (GNMSF)
  • Can United Natural Foods Fight Both Inflation and the Fed?
  • Mullen Automotive Is Ready To Get In Gear
  • Cracker Barrel: A Tasty Treat Or Bad Apple?
  • Defensive Stocks For A Volatile Market
  • Will UPS Be Next to Deliver a Warning?
  • 免費獲取StockNews.com關於Genmab A/S(GNMSF)的研究報告
  • 聯合天然食品能同時對抗通脹和美聯儲嗎？
  • 馬倫汽車已做好準備投入使用
  • 餅乾桶：可口的款待還是壞蘋果？
  • 防禦性股票應對動盪的市場
  • UPS會成為下一個發出警告的公司嗎？

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.

接受Genmab A/S日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genmab A/S和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論